Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The Value of 68Ga-PSMA PET/CT Following Equivocal 18F-NaF PET/CT in Prostate Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Can Computed Tomography Perfusion Predict Treatment Response After Prostate Artery Embolization: A Feasibility Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Acute Tentorial Subdural Hematoma Caused by Rupture of the Posterior Cerebral Artery after Minor Trauma-A Case Report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa) undergoing primary ADT was predictive of the development of CRPC and PCa-specific mortality. The study included 191 patients who commenced ADT from 2000 to 2011. The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low expression. The risks of CRPC and PCa-specific mortality were analyzed using stratified cumulative incidences and a cause-specific COX regression analysis for competing risk assessment. The median follow-up time was 9.8 (IQR: 6.1–12.7) years. In total, 94 and 97 patients presented with low and high AZGP1 expression, respectively. A low AZGP1 expression was found to be associated with a shorter time to CRPC when compared to patients with a high AZGP1 expression (HR: 1.5; 95% CI: 1.0–2.1; p = 0.03). However, the multivariable analysis demonstrated no added benefit by adding the AZGP1 expression to prediction models for CRPC. No differences for PCa-specific mortality between the AZGP1 groups were observed. In conclusion, a low AZGP1 expression was associated with a shorter time to CRPC for PCa patients treated with first-line ADT but did not add any predictive information besides well-established clinicopathological variables.
OriginalsprogEngelsk
Artikelnummer520
TidsskriftDiagnostics
Vol/bind10
Udgave nummer8
ISSN2075-4418
DOI
StatusUdgivet - aug. 2020

ID: 60879479